PDG20 COST-EFFECTIVENESS ANALYSIS OF EZETIMIBE AS THE ADD-ON TREATMENT TO MODERATE-DOSE ROSUVASTATIN VERSUS HIGH-DOSE ROSUVASTATIN IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN CHINA: A MARKOV MODEL ANALYSIS BASED ON NSTE-ACS
Abstract
Authors
H. Yang M. Hu Y. Zhou S. Li